InvestSMART

AVITA Medical, Inc. (ASX:AVH)

ALERT: Price-sensitive ASX Announcement for AVH
Current share price for AVH : $1.145 -0.055 (-4.58%)+
Announcement
Release
15 May 2026 8:23AM
Price at Release
$1.200
Full Release
download
Summary
AVITA Medical's Q1 2026 earnings presentation highlights strong performance improvements compared to the prior year, driven by increased utilization of their RECELL products, including the RECELL GO mini and the new Cohealyx. The company reported a net revenue of USD 19.3 million for Q1 2026, with a gross profit margin of 81.7%. Significant achievements include a reduction in the time to skin grafting by approximately 20 days with Cohealyx, supported by strong clinical validation and surgeon endorsement. AVITA Medical has also secured a 10-year BARDA deal to enhance U.S. burn preparedness, supporting consistent procedure-driven demand. They reaffirmed their 2026 net revenue guidance at USD 80 to 85 million, aiming for 12% to 19% growth over 2025, and are positioned for continued quarterly growth with disciplined cost structures and improved operating leverage.
Key Points
  • Q1 2026 net revenue of USD 19.3 million.
  • Gross profit margin of 81.7%.
  • Cohealyx reduces time to skin grafting by ~20 days.
  • Positive surgeon validation for Cohealyx.
  • Secured a 10-year BARDA deal for U.S. burn preparedness.
  • Reaffirmed 2026 net revenue guidance of USD 80 to 85 million.
  • 12% to 19% growth over 2025 expected.
  • Consistent procedure-driven demand for RECELL products.
  • Positioned for continued quarterly growth in 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.